Improving multidisciplinary tailored care models for bleeding disorders

Expert Review of Hematology · Published 2026-04-02 · DOI 10.1080/17474086.2026.2655968

Authors being retrieved — see the publisher record. https://doi.org/10.1080/17474086.2026.2655968

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Polycythemia vera and metabolic syndrome: is the relationship between the two diseases more than we think? · Expert Review of Hematology · 2026 · Same journal
Challenges faced by women and girls with hemophilia/Carriers: an expert call for closing the diagnosis gap · Expert Review of Hematology · 2026 · Same journal
Social challenges and support needs of patients with hemophilia in Pakistan: a qualitative exploratory study · Expert Review of Hematology · 2026 · Same journal
Autoimmune cytopenias in chronic lymphocytic leukemia in the era of novel drugs · Expert Review of Hematology · 2026 · Same journal
A Review of Disparities in Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma · Expert Review of Hematology · 2026 · Same journal
Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison · Expert Review of Hematology · 2026 · Same journal
An interview with Dr Joshua Richter on his experience as an investigator for linvoseltamab-gcpt - by Reegan Burnell-Clarke (Commissioning Editor) · Expert Review of Hematology · 2026 · Same journal
Reconsidering time from diagnosis to treatment in acute myeloid leukemia: from therapeutic urgency to biologically informed timing · Expert Review of Hematology · 2026 · Same journal
Apparent plateaus during iron chelation in transfusion-dependent β-thalassemia: interpretation and clinical implications · Expert Review of Hematology · 2026 · Same journal
Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia · Expert Review of Hematology · 2026 · Same journal